PHILADELPHIA--(BUSINESS WIRE)--Hemispherx Biopharma, Inc. (AMEX: HEB), a biopharmaceutical company engaged in the clinical development and manufacture of new drug entities for the treatment of seriously debilitating disorders and pandemic disease threats, announced today that new scientific reports featuring its two experimental lead products, (Ampligen® and Alferon-N™), have been accepted by the 2nd International Conference on Avian Influenza. The event will be held at the Pasteur Institute, May 31-June 1, 2007, in Paris, France, and is attended by global healthcare professionals that specialize in the field of pandemic threats, such as influenza.
